Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vivani Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vivani Medical's regulatory disclosures and financial reporting.
Vivani Medical, Inc. filed a Form 8-K to furnish an investor slide presentation under Item 7.01 (Regulation FD Disclosure). The company states that it periodically presents and distributes these slides to the investment community at conferences to provide business updates.
The slide deck, titled “Vivani Medical, Inc. slide presentation” and dated August 17, 2026, is included as Exhibit 99.1. Vivani clarifies that this information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated into Securities Act or Exchange Act filings unless expressly referenced.
Vivani Medical, Inc. reported second-quarter 2026 results and highlighted clinical and strategic progress. All 20 participants in the SLIM-1 Phase 1 trial of NPM-139, a miniature ultra long-acting semaglutide implant for chronic weight management, were enrolled and successfully dosed ahead of schedule, with top-line data expected in November 2026. Vivani also signed a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal technology, and its Cortigent subsidiary entered a definitive merger with Nasdaq-listed ClearOne to form Cortigent Holdings, anticipated to trade under ticker CRGT in the third quarter of 2026.
As of June 30, 2026, Vivani held $20.8 million in cash, cash equivalents and restricted cash, up from $17.6 million at year-end 2025, supported by prior share purchase agreements and January 2026 financings. Second-quarter 2026 research and development expense was $4.5 million and general and administrative expense was $2.4 million, both modestly lower than a year earlier. Net loss for the quarter narrowed to $6.4 million from $7.1 million, with other income of $0.5 million.
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its NanoPortal™ technology, focused on GLP-1 and other chronic-disease therapies. It reported a net loss of $6.4 million for the quarter and $13.2 million for the six months ended June 30, 2026, with no product revenue.
Cash and cash equivalents were $19.9 million (plus $0.9 million restricted cash), total assets $41.6 million, and stockholders’ equity $19.0 million. Operating cash outflow was $12.2 million in the first half of 2026, partly offset by $15.5 million of equity financing, including private placements and a registered direct offering. Management estimates existing cash will fund planned operations only through the second quarter of 2027 and explicitly states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Strategically, Vivani is advancing lead GLP-1 implant candidate NPM-139, has fully enrolled and dosed the SLIM-1 trial with topline data expected November 2026, and entered a non-exclusive evaluation agreement with Novo Nordisk. Vivani is also pursuing a merger of its neurostimulation subsidiary Cortigent with ClearOne, under which Vivani would receive 12,500,000 ClearOne shares and is expected to remain majority owner of the combined Cortigent-focused entity.
Vivani Medical, Inc. reports full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1 trial of NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The randomized, controlled trial evaluates safety, tolerability and pharmacokinetics versus low-dose Wegovy injection in GLP-1 naïve participants in Australia.
NPM-139 uses Vivani’s NanoPortal implant platform, which is being designed to deliver semaglutide continuously for six to twelve months and to allow rapid reversal of drug exposure when needed. SLIM-1 runs over four weeks, with top-line data from the 20-participant study expected in November 2026 and anticipated to inform a planned Phase 2 dose-ranging trial in 2027. Vivani also highlights preclinical studies showing sustainable 20% weight reduction in animal models and a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and the NanoPortal technology.
Vivani Medical, Inc. granted Chief Business Officer Donald Dwyer equity awards consisting of stock options and performance-based RSUs. He received 70000.0000 common stock options with a 10-year term and a 1.3100 exercise price, vesting 25% after one year and monthly over 36 months, subject to continued service. He also received 35000.0000 RSUs, each a contingent right to one common share, vesting in three stages tied to the share price being at or above $3.15 for three consecutive trading days within four years and additional time-based service conditions.
Vivani Medical, Inc. reported equity awards to Chief Medical Officer Lisa Ellen Porter on July 28, 2026. She received stock options for 80,000 shares at a $1.31 exercise price, vesting 25% after one year and monthly over 36 months within a 10-year term, plus 40,000 performance-based RSUs that vest in three stages if the share price reaches $3.15 for three consecutive trading days within four years.
Vivani Medical, Inc. reported that its Chief Financial Officer Anthony Baldor received equity awards consisting of stock options for 75,000 shares at an exercise price of $1.31 per share and 37,500 performance-based RSUs. The options vest 25% after one year then monthly over 36 months and expire in 2036, while the RSUs vest in three stages only if the stock trades at or above $3.15 for three consecutive trading days within four years.
Vivani Medical, Inc. reported equity compensation for Chief Operations Officer Le Truc consisting of a stock option for 160,000 shares of common stock at an exercise price of $1.31 per share, expiring in 2036, and 80,000 performance-based RSUs tied to achieving a $3.15 share-price hurdle over a four-year term. The option has a 10-year term and vests 25% after one year, then monthly over 36 months, while the RSUs vest in three tranches based on this market condition and time-based anniversaries, subject to continued service.
Vivani Medical, Inc. granted Chief Executive Officer Adam Mendelsohn 200,000 stock options and 100,000 performance-based RSUs on July 28, 2026. The options have a $1.31 exercise price, a 10-year term, and vest 25% after one year then monthly for 36 months. Each RSU equals one share and vests in three stages tied to Vivani's stock trading at or above $3.15 for three consecutive trading days, with additional tranches one and two years after that date; the RSUs expire if this price condition is not met within four years and all vesting requires continued service.
BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Vivani Medical, Inc. reported that director Daniel Bradbury received a grant of 7,965 non-qualified stock options to buy common stock at 1.3000 per share. The options have a 10-year term, expire on July 26, 2026, and vest quarterly through December 31, 2026, subject to his continued service. The award, held directly, was issued under the non-employee director compensation policy in lieu of $8,000 in cash retainer fees for increased committee service, leaving him with 7,965 options reported in this grant.